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OBJECTIVE—We showed that 17-estradiol (E2) favors pan-
creatic -cell survival via the estrogen receptor- (ER) in mice.
E2 activates nuclear estrogen receptors via an estrogen response
element (ERE). E2 also activates nongenomic signals via an
extranuclear form of ER and the G protein–coupled estrogen
receptor (GPER). We studied the contribution of estrogen recep-
tors to islet survival.
RESEARCH DESIGN AND METHODS—We used mice and
islets deﬁcient in estrogen receptor- (ERKO
/), estrogen
receptor- (ERKO
/), estrogen receptor- and estrogen recep-
tor- (ERKO
/), and GPER (GPERKO
/); a mouse lacking
ER binding to the ERE; and human islets. These mice and islets
were studied in combination with receptor-speciﬁc pharmaco-
logical probes.
RESULTS—We show that ER protection of islet survival is
ERE independent and that E2 favors islet survival through
extranuclear and membrane estrogen receptor signaling. We
show that ER plays a minor cytoprotective role compared to
ER. Accordingly, ERKO
/ mice are mildly predisposed to
streptozotocin-induced islet apoptosis. However, combined elim-
ination of ER and ER in mice does not synergize to provoke
islet apoptosis. In ERKO
/ mice and their islets, E2 partially
prevents apoptosis suggesting that an alternative pathway com-
pensates for ER/ER deﬁciency. We ﬁnd that E2 protection of
islet survival is reproduced by a membrane-impermeant E2
formulation and a selective GPER agonist. Accordingly,
GPERKO
/ mice are susceptible to streptozotocin-induced in-
sulin deﬁciency.
CONCLUSIONS—E2 protects -cell survival through ER and
ER via ERE-independent, extra-nuclear mechanisms, as well as
GPER-dependent mechanisms. The present study adds a novel
dimension to estrogen biology in -cells and identiﬁes GPER as
a target to protect islet survival. Diabetes 58:2292–2302, 2009
P
reserving insulin secretion by the pancreatic
-cells is critical in both type 1 and the late stages
of type 2 diabetes. In type 1 diabetes, the death of
insulin-producing -cells of the pancreas by apo-
ptosis leads to insulin dependence. Insulin replacement
therapy by pancreatic islet transplantation is a treatment
that most closely replicates normal physiological condi-
tions for treatment of type 1 diabetes (1), but its effective-
ness is reduced by the loss of functional islet mass from
apoptosis, impairing the survival of islet grafts. Similarly,
in the late stages of type 2 diabetes, evidence of -cell
apoptosis is documented in animal models (2,3) and in
humans (4). Thus, in the absence of novel immunotherapy
and antiapoptotic drugs, novel strategies to protect insu-
lin-producing cells in vivo represent a major opportunity
for therapeutic intervention. One promising approach to
protect -cells from apoptosis involves the cytoprotective
actions of estrogens. In addition to its reproductive func-
tions, the female sex steroid 17-estradiol (E2) is a neuro-
protective hormone against multiple oxidative and
proapoptotic insults in vivo and in vitro, acting via classic
estrogen receptors (rev. in 5). Recently, we reported that
E2 protects -cells from streptozotocin (STZ)-induced
apoptosis in mice of both sexes via the estrogen receptor
(ER)- (6). In cultured mouse and human islets, E2 has
potent antiapoptotic properties against proinﬂammatory
cytokines and reactive oxygen species (6,7). E2 acts via
classic estrogen receptors, ER and ER (8). In ER-
deﬁcient female mice, E2 still partially protects -cell
survival via an alternative pathway (6), suggesting that
ER may mediate the effects of E2 in the absence of ER.
The G protein–coupled estrogen receptor (GPER), also
known as GPR30, has been recognized as a membrane
receptor for estrogens that mediates nongenomic signals
(9). GPER is expressed in islets and has recently been
suggested to mediate the estrogenic effect on islet insulin
release (10). We analyzed the contribution of ER,E R ,
and GPER to islet survival. We used mice individually
deﬁcient in ER,E R ,E R  and ER, and GPER; a mouse
lacking ER binding to the ERE; and human islets. These
mutant mice and islets were exposed to oxidative stress
using STZ or hydrogen peroxide, respectively, in combina-
tion with the use of speciﬁc pharmacological probes.
RESEARCH DESIGN AND METHODS
Generation of mutant mice. The generation of ERKO
/, ERKO
/, and
GPERKO
/ mice has previously been described (6,11). Mice were studied
between 7–9 weeks of age. Mice with a mutation of the DNA-binding domain
of ER (AA allele) that eliminates ER binding to the ERE (ERKO
AA/) were
kindly provided by Larry Jameson (12). The ERKO
AA/ mice were generated
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AA/ with heterozygote female ER null
mice (ERKO
/). Because female ERKO
AA/ are infertile, they cannot be
crossed with male ERKO
AA/, and therefore ERKO
AA/AA mice cannot be
generated. All animal experiments were approved by Northwestern University
Animal Care and Use Committee in accordance with the National Institutes of
Health Guide for the Care and Use of Animals.
Metabolic studies. Glucose tolerance tests (2 g/kg) and corresponding area
under the curve for glucose (minus basal) and glucose-stimulated insulin
secretion (3 g/kg) were performed as described (6). Serum insulin concentra-
tions were measured by ELISA using mouse standards (Crystal Chem,
Chicago, IL) (6).
Exogenous substance infusion and induction of experimental diabetes.
Diabetes was induced in 8-week-old female mice by a single intraperitoneal
injection of 150 mg/kg of STZ as described (6). Blood glucose was measured
every 48 h after STZ injection with a glucose monitor. At day 8 after STZ
injection, mice were killed and pancreata collected.
Pancreas insulin concentration. Whole pancreata were collected, weighed,
and homogenized in acid/ethanol. Pancreas homogenates were centrifuged,
and the supernatant was used to measure pancreas insulin concentration by
radioimmunoassay (6).
Islet culture and compounds stimulation. Islet isolation was performed as
previously described (6). Islets were cultured in phenol red–free RPMI medium
containing 11 mmol/l glucose, 10% charcoal stripped FBS, 1 mmol/l glutamine,
100 units/ml penicillin, 100 g/ml streptomycin. Islets were incubated with
E2 (10
8 M, steraloids), propyl-pyrazole-triol (PPT, 10
8 M) (13), methyl-
piperidino-pyrazole (MPP, 10
7 M) (14), diarylpropionitrile (DPN, 10
8 M)
(15), tetrahydrochrysene (THC, 10
7 M) (16), estrogen-dendrimer conjugate
(EDC) (10
8 M) (17) or G-1 (10
7 M) (18) for 48 h. Ethanol was used as the
vehicle. After 48 h estrogen receptor ligands treatment, islets were exposed to
H2O2 (100 mol/l, Sigma) for the last 5 h before assessment of apoptosis. PPT,
EDC, and DPN were a gift from John A. Katzenellenbogen, University of
Illinois at Urbana.
Antibodies. In immunohistochemical studies, the following primary antibod-
ies were used: guinea pig anti-insulin (1:1,000, Linco Research), rabbit
anti-glucagon (1:1,000, Linco Research), mouse anti-ER (1:100, 1D5, Zymed
Laboratories), and goat anti-ER (1:100, Y-19, Santa Cruz Biotechnology).
Where tyramide signal ampliﬁcation was performed, biotinylated secondary
antibodies were used. Where signal was not ampliﬁed, FITC- or Cy3-conju-
gated secondary antibodies were used. Secondary antibodies were raised in
donkey (Jackson ImmunoResearch) and used at a 1:200 dilution.
Immunohistochemistry. Mouse pancreases were ﬁxed and processed for
immunohistochemistry as described (6). For staining with ER and ER,
Alexa 568 tyramide signal ampliﬁcation kit (Molecular Probes) was used.
Sections were counterstained with DAPI (1:50,000, 5 min) before confocal
visualization (Zeiss LSM 510). For MIN6 immunolabeling, cells were seeded on
coverslips and grown until 80% conﬂuency. Twenty four hours before
ﬁxation, cells were maintained in phenol red–free DMEM media (Sigma). Cells
were treated with E2 (10
8 M) or ethanol vehicle for 1 h, washed with warm
PBS, and ﬁxed in 10% neutral-buffered formalin for 20 min. For labeling of
mitochondria, live cells were incubated for 45 min with 100 nmol/l Mito-
Tracker reagent (Molecular Probes). Cells were permeabilized (0.1% Triton
X-100/PBS), blocked (1 h, 5% normal donkey serum), labeled with antibodies,
counterstained, and visualized with confocal or deconvolution (Applied
Precision DeltaVision) microscopy.
Measurement of apoptosis by nuclear morphology. Apoptosis was in-
duced by H2O2 (100 mol/l, 5 h) in groups of 100 islets per condition. After 5 h
incubation with H2O2, islets were collected and washed with PBS. Single-cell
suspensions were obtained by incubating the islets in 500 l Accutase solution
(Innovative Cell Technologies, San Diego, CA) at 37°C for 15 min, followed by
gentle pipetting. To score apoptosis, cells were ﬁxed with 1.25% glutaralde-
hyde for 15 min at room temperature and nuclei were stained with 10 g/ml
bisbenzimide (Hoechst 33258; Sigma) for 15 min at room temperature. The
percentage of cells with apoptotic nuclei (condensed or fragmented) was
determined by ﬂuorescence microscopy (E400 Nikon Eclipse). For each
condition, at least 200 cells were scored in duplicate. Results are representa-
tive of at least three independent experiments.
Assay for active caspase 3. Caspase activity was measured in mouse islets
using Caspase-Glo 3/7 assay kit (Promega). Brieﬂy, after 5 h incubation with
H2O2 (100 mol/l, Sigma), islets were centrifuged for 5 min at 1,200 rpm and
transferred to a 96-well plate in 100 l medium. Islets were then lysed with 100
l Caspase-Glo 3/7 reagent and incubated at room temperature for 30 min.
Luciferase activity was measured using a Synergy 2 Multi-Mode Microplate
Reader (BioTek). Values are reported as relative luciferase units corrected for
total protein concentration.
Plasmid transfection and luciferase assay. MIN6 cells were cultured in
DMEM high medium and plated in 24-well plates (10  10
4 cells/well). Before
the transfection, cells were cultured overnight in DMEM phenol red–free
medium. Cells were incubated with the mixture of 2 l Lipofectamine 2000
(Invitrogen) and 0.8 g of a reporter construct containing an ERE (ERE-Luc)
for 6 h (19). Cells were treated for 24 h with either E2 (10
8M), E2-BSA
(10
8M), EDC (10
8M), or G1 (10
7M). For measurement of luciferase
activity, cells were lysed with Cell Culture Lysis Reagent (Promega). After
centrifugation, 2–6 g of protein were used in a Luciferase Assay System
(Promega). Values are reported as relative luciferase units corrected for total
protein concentration.
Western blot analysis. Cells were homogenized in lysis buffer as described
(20). Thirty micrograms of protein was analyzed by SDS-PAGE. Cytoplasmic
and nuclear fractions were extracted using a commercial kit (Pierce Biotech-
nology), and ER expression was determined by immunoblotting with mouse
anti-ER antibody (1:100, MC-20, Santa Cruz Biotechnology). GPER expres-
sion was determined by immunoblotting with a polyclonal goat anti-GPR30
antibody (1:400, Santa Cruz Biotechnology).
Statistical analysis. Results are presented as means  SE unless otherwise
stated. Data were analyzed using the unpaired Student’s t test. Cumulative
incidence of diabetes was determined by Kaplan-Meier estimates, and statis-
tical analysis of differences was determined by log-rank test. A value of P 	
0.05 was considered signiﬁcant.
RESULTS
ER protects islet survival independently of the
classic estrogen response element. We previously re-
ported that ER-deﬁcient mice lose cytoprotection from
circulating E2 and are predisposed to -cell apoptosis
when their islets are exposed to oxidative stress in vivo
(6). In the classic estrogen receptor signaling pathway,
E2-activated ER binds as a homodimer to either an ERE
or a non-ERE tethered promoter to initiate gene transcrip-
tion (21). To investigate whether an ER-ERE or non-ERE
signaling mechanism protects -cell survival in vivo, we
used an ER knock-in mouse with a mutation of the
DNA-binding domain of ER that eliminates ER binding
to the ERE (ERKO
AA/) (12). To produce -cell apoptosis
in vivo, we used a single high-dose injection of STZ (150
mg/kg) in female mice. STZ provokes an increase in islet
reactive oxygen species as can be encountered after
exposure to hyperglycemia or cytokines in type 1 diabetes
and type 2 diabetes (22,23). We compared the sensitivity to
STZ in ERKO
AA/ mice with one knock-in AA allele with
that of ERKO
/ and ERKO
/ mice with one or no
functional ER allele. This enabled us to study the effect of
the unique AA allele and non-ERE signaling on the predis-
position to -cell apoptosis in vivo. Compared with the
null ERKO
/, the ERKO
/ showed a minor predispo-
sition to STZ-induced insulin-deﬁcient diabetes, conﬁrm-
ing a minor effect of ER gene dosage (6). A single AA
allele without ERE binding was sufﬁcient to protect
ERKO
AA/ female mice from STZ-induced insulin-deﬁ-
cient diabetes to an extent similar to that observed in
ERKO
/ mice (Fig. 1A–D), demonstrating that ER
protection of -cell survival is independent of the classic
ERE-dependent pathway.
ER prevents islet apoptosis via rapid, extranuclear
actions. Because activation of ER protects -cell sur-
vival via an ERE-independent mechanism, we explored the
possibility that ER favors survival through rapid, ex-
tranuclear actions. We observed colocalization of ER
with insulin-producing -cells in mouse and human pan-
creatic islets with a predominant cytosolic localization
(Fig. 2A and B). In mouse MIN6 -cells, we observed ER
predominantly in the cytosol, in close vicinity to the
plasma membrane and mitochondria (Fig. S1A and B,
available in an online appendix at http://diabetes.
diabetesjournals.org/content/early/2009/07/08/db09-0257/
suppl/DC3). The predominant cytosolic localization of
ER in -cells, although it exhibits a predominant nuclear
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S1C, available in an online appendix), suggested that ER
regulates -cell biology through extranuclear signaling
pathways. To explore that hypothesis, we ﬁrst studied the
subcellular localization of ER by confocal microscopy in
MIN6 -cells. In the absence of E2,E R  showed a dual
cytosolic and nuclear immunoreactivity (Fig. 2C). E2 stim-
ulation for 1 h provoked a disappearance of nuclear ER
immunoreactivity and an increased density of ER ex-
tranuclear signal (Fig. 2C). This pattern was similarly
observed using two different ER antibodies (supplemen-
tal Fig. S2, available in an online appendix). To explore the
mechanism of alteration in ER signal between cytosol
and nucleus, we performed subcellular fractionation in
MIN6 cells. After E2 stimulation, we observed no change in
the amount of the classic 67kDa ER isoform between the
nucleus and cytosolic fractions (Fig. 2D), demonstrating
that there is no transfer of ER from the nucleus to the
cytosol. The E2-induced alteration of ER nuclear signal
into irregular punctuate structures was interpreted as an
organization of nuclear speckles symbolic of active tran-
scription start sites in ﬂuorescent microscopy (24). A
similar appearance was observed after E2 stimulation in a
classic model of ER nuclear actions, the human breast
cancer MCF7 cells (supplemental Fig. S1E, available in an
online appendix). We hypothesized that the increased ER
A
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FIG. 1. ER protects islet survival via ERE-independent pathway. A: Cumulative incidence of diabetes (random-fed blood glucose >250 mg/dl) in
wild-type, ERKO
/, ERKO
/, and ERKO
AA/ mice (n  10–15) after STZ challenges (150 mg/kg). B: Random-fed blood glucose was measured
after STZ injection (day 8). C: The ratio of random-fed insulin (pg/ml)/glucose (mg/dl) at day 8 was used as an index of insulin deﬁciency. Values
represent the means  SE. D: Pancreatic insulin concentration was measured after STZ injection (day 8). Values are represented as scatter plot.
*P < 0.05. WT, wild type.
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FIG. 2. E2 prevents -cell apoptosis via an extranuclear estrogen receptor. A: Female pancreas section showing a single islet with ER immunoﬂuo-
rescent staining in -cells (red). The insulin (green), nuclear (DAPI, blue), and triple staining (merge) are shown. B: Immunoﬂuorescent staining of
ER in cultured human islets. C: Immunoﬂuorescent staining of ER (MC20) in MIN6 cells treated with vehicle or E2 (10
8M) for 1 h and imaged with
deconvolution microscopy. D: Subcellular fractionation showing ER expression by Western blotting from total lysates (TL), cytoplasmic (Cyt), and
nuclear (Nucl) extracts of MIN6 cells after E2treatment for 1 h. E: Relative luciferase activity in MIN6 cells transfected with an ERE reporter construct
and treated with E2, EDC, or E2-BSA (10
8M). F: Percentage of apoptotic cells in cultured mouse islets. G: Percentage of apoptotic cells in cultured
human islets. Islets from (F) and (G) were treated with E2, EDC, or E2-BSA (10
8M) for 48 h, followed by exposure to H2O2 (100 mol/l) for the last
5 h. Apoptosis was assessed by nuclear fragmentation. Values represent the means  SE of ﬁve independent experiments. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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extranuclear and antiapoptotic signaling that is dissoci-
ated from ER nuclear presence. To address this latter
possibility, we studied E2 protection from apoptosis in
cultured islets after acute exposure to H2O2 (100 mol/l)
to mimic the oxidative injury observed in vivo after
exposure of islets to a single high dose of STZ (25). We
used two pharmacological probes speciﬁc for estrogen
receptor nongenomic actions: 1) A membrane-impermeant
preparation of E2, which is bound to a macromolecule,
namely, BSA (E2–BSA). The response to the membrane-
impermeant compounds is used as a gold standard to
deﬁne membrane-initiated responses (26). 2) A novel EDC
that activates cytosolic estrogen receptor pathways but
remains outside the nucleus and is ineffective in stimulat-
ing transcription of estrogen target genes (17). Compared
with E2, neither E2-BSA nor EDC showed transcriptional
activity in MIN6 -cells on a reporter construct containing
an ERE (Fig. 2E). Exposure of mouse and human islets to
E2,E 2-BSA, or EDC produced a similar and robust protec-
tion against H2O2-induced apoptosis (Fig. 2F and G).
Elimination of ER mildly predisposes to STZ-
induced diabetes. In ERKO
/ mice, E2 still partially
protects -cell survival via an alternative pathway (6),
making ER a candidate for mediating the effects of E2 in
the absence of ER. We observed ER expression in
mouse and human pancreatic -cells and MIN6 cells with
a cytosolic localization (Fig. 3A–C), although it exhibits a
predominant nuclear localization in reproductive tissues
(supplementary Fig. S1D, available in an online appendix).
ER localization was not inﬂuenced by E2 treatment
(supplementary Fig. S3, available in an online appendix).
We sought to determine whether ER exerts E2 protection
of -cell survival using ER-deﬁcient mice (ERKO
/
mice). In basal condition, female ERKO
/ mice showed
no abnormality of fasting and fed blood glucose (supple-
mental Table 1, available at an online appendix). After
exposure to STZ, as previously described (6), female
wild-type mice were protected and retained normal blood
glucose and pancreas insulin concentrations; conversely,
female ERKO
/ mice were vulnerable to STZ and ex-
hibited mild hyperglycemia and moderate insulin deﬁ-
ciency compared to wild type (Fig. 3 D–G). Male wild-type
and ERKO
/ mice were exposed to a less diabetogenic
single low dose of STZ (100 mg/kg). Such a low dose of
STZ caused a moderate increase in diabetes incidence in
male wild-type mice, while it predisposed to insulin-
deﬁcient diabetes in male ERKO
/ mice (supplementary
Fig. S4, available in an online appendix).
E2 protects islet survival in the absence of ER and
ER in mice. Because individual deletion of ER and ER
impairs islet resistance to STZ in mice, we hypothesized
that combined elimination of both ER and ER would
synergize to abolish E2 protection of islet survival. We thus
compared the role of ER and ER in islet survival from
STZ injury in the single ERKO
/, ERKO
/, and the
double ERKO
/ littermate female mice. We conﬁrmed
that exposure to STZ caused a more severe predisposition
to insulin-deﬁcient diabetes in female ERKO
/ mice
compared to littermate ERKO
/ mice (Fig. 4A–D). How-
ever, after exposure to STZ, the dual absence of ER and
ER in the double ERKO
/ did not aggravate the
predisposition to insulin-deﬁcient diabetes, suggesting
that in the absence of both estrogen receptors, E2 still
protects via an alternative pathway (Fig. 4A–D). Thus, to
determine the extent to which, in the absence of ER and
ER, circulating E2 could still protect the ERKO
/,w e
suppressed endogenous E2 production by ovariectomy
(OVX). OVX further aggravated the predisposition to STZ
in female ERKO
/ mice while, conversely, E2 treat-
ment of ERKO
/ OVX mice restored protection from
STZ-induced insulin-deﬁcient diabetes (Fig. 4A–D). Similar
ﬁndings were observed in male mice. The double
ERKO
/ mice did not show a more severe predisposi-
tion to STZ compared to the single ERKO
/ and
ERKO
/ male littermates (supplementary Fig. S5, avail-
able in an online appendix).
E2 protects islet survival in the absence of ER and
ER in vitro. The individual contribution of ER and ER
to islet survival was next examined in cultured wild-type
mouse islets using PPT and DPN, which are ER- and
ER- selective agonists, respectively (13,15). After induc-
tion of apoptosis with H2O2, we observed a similar pre-
vention of apoptosis by E2 and PPT treatments (Fig. 5A);
accordingly, E2 protection was impaired using the ER-
selective antagonist MPP (Fig. 5A) (14). DPN provided
only minor islet protection, but E2 protection from islet
apoptosis was impaired using the ER-selective antagonist
THC (Fig. 5A). We next examined E2 protection of islet
survival in ER- and ER-deﬁcient mouse islets. H2O2
provoked an increase in apoptotic cells from wild-type
islets, which was prevented by E2 (Fig. 5B). E2 protection
was impaired in ERKO
/ islets. Conversely, E2 protec-
tion was retained in ERKO
/ islets. In addition, consis-
tent with the in vivo data, in the absence of both ER and
ER,E 2 protection of apoptosis was retained in
ERKO
/ islets (Fig. 5B). E2 antiapoptotic action via
ER and ER was further investigated using a luminescent
assay for activated caspase-3, the “executioner” of apopto-
sis. E2 prevented caspase-3 activation that was mimicked
by PPT and DPN treatment. However, E2 prevention of
caspase-3 activation was abolished in ERKO
/ islets but
was retained in ERKO
/ islets (Fig. 5C). We also
observed that E2, PPT, and to a lesser extent DPN protect
human islets from H2O2-induced apoptosis (Fig. 5D).
Lastly, the antiapoptotic protection of E2 and PPT was
reproduced in MIN6 cells demonstrating a direct effect on
-cells (Fig. 5E). Thus, E2 protects -cell survival in vivo
and in cultured islets via ER and ER, with a predomi-
nant ER effect. However, in the absence of ER and ER,
E2 still protects -cell survival.
GPER is important for islet survival. Recently, GPER,
also known as GPR30, has been recognized as a membrane
receptor for estrogens that mediates nongenomic, rapid
signals (9,27). We observed that GPER protein is ex-
pressed in mouse islets, human islets, and MIN6 cells (Fig.
6A). Because E2 protects -cell survival via a membrane-
initiated mechanism (Fig. 2F and G) and in the absence of
ER and ER (Fig. 4 and 5), we investigated the possibility
that E2 cytoprotection is mediated via GPER. We investi-
gated the importance of GPER using mice deﬁcient in the
receptor (GPERKO
/). When studied on a regular chow,
female wild-type and GPERKO
/ littermate mice showed
similar fasting and fed blood glucose and serum insulin
concentrations (Table 1). We observed no difference be-
tween wild-type and female GPERKO
/ mice with regard
to intraperitoneal glucose tolerance, glucose-stimulated
insulin secretion, fed pancreas insulin concentrations (Ta-
ble 1), and islet architecture (supplementary Fig S6, avail-
able in an online appendix). However, after exposure to
STZ, compared to wild-type female mice, GPERKO
/
female mice lost the protection of endogenous E2 and
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loss of -cells and decrease in pancreas insulin concentra-
tion (Fig. 6B–F). The predisposition to STZ-induced diabe-
tes was not observed in male GPERKO
/ mice
(supplementary Fig S7, available in an online appendix).
We next studied the importance of GPER in cultured
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/ mice. We
used the GPER agonist G1, which selectively activates
GPER in a cellular environment containing ER and ER
(18). G1 showed no transactivating activity on ERE-depen-
dent gene expression in -cells (Fig. 6G). We found that G1
prevents apoptosis as efﬁciently as E2 in wild-type mouse
islets and human islets (Fig. 6H and J). We observed that
E2 cytoprotection, measured either via nuclear morphol-
ogy or caspase-3 activation, was retained in mouse
GPERKO
/ islets compared to wild-type islets, demon-
strating that ER can compensate for the absence of
GPER in GPERKO
/ islets (Fig. 6H and I). Conversely,
G1 cytoprotection was abolished in GPERKO
/ islets,
demonstrating its high selectivity toward GPER compared
with ER and ER (Fig. 6H and I). We conﬁrmed that G1
protection from apoptosis was observed in human islets
(Fig. 6J) and that G1 directly acts on -cells (Fig. 6K).
Thus, E2 protection is mediated via ER,E R , and GPER
with a direct effect on the islets and with a predominant
ER effect, via ERE-independent, extranuclear, and rapid
mechanisms.
DISCUSSION
Recently, we reported that E2 protects -cell survival in
mice of both sexes via ER (6). Many actions of E2,
including the feminizing effects, are mediated via a classic
and nuclear ER-activating transcription through an ERE
(21). Here, using a mouse model lacking ERE signaling, we
show that ER cytoprotection of islets in vivo is ERE
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tion in -cells, and we ﬁnd that E2 favors -cell survival via
activation of extranuclear and perhaps membrane estro-
gen receptors with a predominant ER effect. This ﬁnding
extends the observation of Kousteni et al. (28), suggesting
that the antiapoptotic actions of E2 in osteoblasts and
ﬁbroblasts are mediated via the ligand-binding domain of
ER and ER with similar efﬁciency, and can be dissoci-
ated from the transcriptional activity of the receptors.
Thus, unlike in classic estrogen receptor genomic actions
where E2-activated ER and ER signal in opposite ways
from an AP1 element (29), with regard to extranuclear,
antiapoptotic actions, ER and ER signal survival in
similar direction. Indeed, the coexpression of both ER
and ER in -cells does not demonstrate evidence of ER
antagonism of ER action because pharmacological inhi-
bition or genetic elimination of ER in islets does not
enhance E2 cytoprotection via ER. However, despite the
apparent antiapoptotic action of ER and ER, the com-
bined elimination of these receptors does not synergize to
abolish E2 cytoprotection after exposure of islets to acute
oxidative stress. This suggests that ER and ER favor
islet survival using nonredundant and distinct cellular
pathways.
The second important ﬁnding is that the membrane G
protein–coupled receptor, GPER, favors islet survival.
GPER is a 7-transmembrane orphan G protein–coupled
receptor that responds to E2 with rapid cellular signaling
(9). GPER has been localized to either the plasma mem-
brane (30) or the endoplasmic reticulum (9). The physio-
logical function of GPER in vivo is still largely unknown.
The existence of a membrane G protein–coupled receptor
unrelated to ER and ER and that may be GPER has been
reported in -cells (31,32). Recently, Martensson et al. (10)
reported that GPER-deﬁcient mice display altered E2-
stimulated insulin release from isolated islets associated
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suggesting that GPER is involved in islet biology. Because
E2 protects -cell from apoptosis (6,7) and recent studies
have implicated GPER in cell survival (33,34), we hypoth-
esized that GPER favors -cell survival. We observe that
GPER deﬁciency in female mice does not alter -cell
function or glucose homeostasis on a normal rodent chow.
This different phenotype with the previous report (10) may
be related to the different genetic background of the mice
used in both studies and/or the greater ability of our
GPERKO
/ mice to compensate for the loss of GPER via
ER. We ﬁnd that elimination of GPER predisposes to
STZ-induced islet apoptosis after exposure to acute oxida-
tive stress in female mice. In addition, we show that
pharmacological activation of GPER by G1 is efﬁcient in
protecting oxidative stress–induced apoptosis in cultured
islets. The observation that G1 cytoprotection is lost in
cultured GPER-deﬁcient islets further supports the func-
tional signiﬁcance of GPER in islet survival. However, the
maintenance of E2 cytoprotection from apoptosis in cul-
tured GPER-deﬁcient islets demonstrates that ER and
ER can compensate for GPER deﬁciency. Conversely, we
conﬁrm that E2 cytoprotection is impaired in ER-
deﬁcient islets and can be compensated, only partially, by
GPER or ER. Thus, ER is the major E2 receptor to favor
islet survival in mice.
A recent report has challenged the initial concept that
GPER is indeed an estrogen receptor in vivo based on the
observation that loss of GPER in mice does not alter
estrogenic responses in reproductive organs that express
GPER (35). However, other investigators reported that GPER
mediates estrogen action in mice. For example, GPER is
necessary for the normal estrogenic response on longitu-
dinal bone growth (36). In addition, GPER-deﬁcient mice
lose E2-stimulated insulin release, arguing that GPER
mediates E2 response in pancreatic islets (10). Thus, when
referring to in vivo models, GPER appears to mediate E2
response in several tissues.
E2 binds a membrane-localized ER, which signals
through a large protein signalosome at the plasma mem-
brane. This complex consists of scaffold proteins (caveo-
lin-1, MNAR), linker proteins (Shc), nonreceptor tyrosine
kinases (Src), threonine/serine kinases (p85 subunit of PI3
kinase, Akt), and growth factor receptors (EGFR, IGF1R)
(37). It is possible that membrane-localized ER signals by
recruiting GPER from the endoplasmic reticulum or the
plasma membrane (38). Our studies do not rule out this
latter possibility because a membrane-impermeant formu-
lation of E2 (E2-BSA) is as efﬁcient as E2 or the selective
ER agonist PPT in protecting islet survival. Thus, E2
could either bind a membrane ER, which would then
signal through GPER, or both ER and GPER, together
utilizing the same signaling pathway. Studies are ongoing
in our laboratory to dissect the signaling pathways of
estrogen receptor cytoprotection in -cells.
The protection by E2 described here in vivo in global
estrogen receptor–deﬁcient mice reﬂects the loss of estro-
gen receptor signaling in all tissues that express these
receptors. Therefore, alteration in interorgan communica-
tion and metabolic regulation because of loss of estrogen
receptors in a distant organ may also indirectly impair islet
survival via circulating factors without a direct effect of E2
on -cells. For example, the predisposition to STZ ob-
served in vivo in estrogen receptor–deﬁcient mice could
be enhanced by subtle differences in glucose concentra-
tion or adipose production of proinﬂammatory cytokines
(39). However, the therapeutic effects of estrogen receptor
ligands obtained in cultured human islets have therapeutic
implications in islet transplantation. The feminizing effects
of estrogens limit their clinical application to protect islet
survival in men and in some women. However, the obser-
vation that E2 utilizes extranuclear and membrane path-
ways that are sex nonspeciﬁc may help identify and
develop new ligands that protect -cells and allow reten-
tion of the beneﬁcial effects of sex hormones in islets
while lacking the mitogenic actions predisposing to hor-
mone-dependent cancers.
In summary, E2 plays a major role in protecting -cells
from apoptosis that is mediated through ER,E R , and
GPER. The present study adds a novel dimension to
estrogen biology in -cells and identiﬁes GPER as a new
target to protect islet survival.
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